Heparin

證據等級: L5

預測適應症: 10 個

Heparin: From Anticoagulation to Thrombophilia due to Protein C Deficiency (Autosomal Recessive)

One-Sentence Summary

Heparin is a well-established parenteral anticoagulant used for the prevention and treatment of thromboembolic events, acting through antithrombin III (ATIII) to inhibit thrombin and Factor Xa. The TxGNN model predicts it may be effective for Thrombophilia due to Protein C Deficiency (Autosomal Recessive), with no clinical trials and no publications currently indexed in major databases for this specific indication — a gap that may reflect uncaptured real-world clinical use rather than a true absence of evidence.

Quick Overview

Item	Content
Original Indication	Anticoagulation (thrombosis prevention and treatment) — no Singapore HSA registration found
Predicted New Indication	Thrombophilia due to Protein C Deficiency, Autosomal Recessive
TxGNN Prediction Score	99.29%
Evidence Level	L4
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the source database. Based on established pharmacology, Heparin is a sulfated glycosaminoglycan that functions by binding and activating antithrombin III (ATIII). Activated ATIII then rapidly inhibits thrombin (Factor IIa), Factor Xa, and — to a lesser degree — Factors IXa, XIa, and XIIa, shifting the coagulation balance decisively towards an anti-thrombotic state.

Autosomal recessive Protein C deficiency creates a severe hypercoagulable state because Protein C normally degrades activated Factor Va and Factor VIIIa — two critical amplifiers of the coagulation cascade. Without functional Protein C, these factors accumulate unchecked, driving excessive thrombin generation and recurrent thrombosis from early life. Heparin addresses this downstream by providing a "bypass" anticoagulant mechanism: rather than restoring Protein C function, it directly neutralises the excess thrombin and Factor Xa generated by the unopposed Factor Va/VIIIa activity.

This mechanistic connection is clinically plausible. Heparin is already applied in practice to manage acute thrombotic episodes in patients with hereditary thrombophilias, including severe Protein C deficiency, as an immediate anticoagulant bridge. The high TxGNN prediction score likely reflects the well-established co-occurrence of heparin and Protein C deficiency in the biomedical knowledge graph, and the absence of trial or publication records may represent a data-capture gap — known clinical use that has not been formally registered as an indication — rather than a genuine absence of supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for this specific indication.

Literature Evidence

Currently no related literature available for this specific indication.

Singapore Market Information

Heparin (DB01109) is not registered with the Health Sciences Authority (HSA) of Singapore. No product authorisation records are available in the current dataset.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for heparin use in autosomal recessive Protein C deficiency is scientifically sound and consistent with established anticoagulation principles; however, no registered clinical trials or indexed peer-reviewed publications specifically document this indication, leaving the evidence at a preclinical/mechanistic level (L4). Compounding this, Singapore regulatory data is entirely absent and key safety information — including bleeding-risk warnings and contraindications — has not been retrieved, making a full safety assessment impossible at this stage.

To proceed, the following is needed:

Retrieve Singapore HSA label or equivalent international prescribing information (e.g., FDA, EMA package insert) to assess bleeding warnings, contraindications, and monitoring requirements
Obtain mechanism of action data from DrugBank (DB01109) to formalise MOA documentation for the dossier
Conduct a targeted literature search to confirm whether heparin use in Protein C deficiency has been captured in observational studies, registry reports, or case series not indexed in the current evidence pack
Determine whether this indication already appears in Singapore or international clinical practice guidelines for inherited thrombophilia management — if so, this may represent an existing (unlabelled) clinical use rather than a true repurposing opportunity
If a repurposing pathway is pursued, define the target patient population (acute thrombosis vs. long-term prophylaxis), appropriate dosing regimen, and monitoring protocol (APTT or anti-Xa levels) specific to this rare genetic condition
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.